Abogen Biosciences

Abogen Biosciences (艾博生物) is a Suzhou-based Chinese mRNA company working across vaccines and therapeutics. It broke into the spotlight in August 2021 with a Series C of over $700 million — one of the largest rounds in China's mRNA space — in which Gaorong participated , followed three months later by a $300 million Series C+ co-led by SoftBank Vision Fund and existing shareholder 5Y Capital . Qiming Venture Partners is also an investor, and its 2025 portfolio updates sketch where the pipeline has moved since: two self-developed mRNA vaccines entering Phase 1 trials in Guangxi , an IND clearance for a lyophilized RSV mRNA vaccine , and a push into mRNA oncology — an EGFR-mutant tumor vaccine presented at AACR 2025 and ABO2102, a multi-KRAS-mutation tumor vaccine that received IND clearance in mid-2025 . In short: one of China's best-funded mRNA platforms, shifting from the COVID-era vaccine race toward oncology and broader infectious-disease programs.